Current developments in herpes simplex virus vaccines

Abstract

The need for the development of an effective vaccine to limit the spread of herpes simplex virus and its associated morbidity and mortality has become more apparent with a better knowledge of the high prevalence of infection. Advances in our understanding of the basis of protective responses and the mechanisms of antigen processing and presentation have led to progress in vaccine development. Research on rationally attenuated live virus, replication-defective virus and subunit vaccines, in addition to that on adjuvants, is promising, and has led to several human clinical trials currently in process.